Archeon Medical
PrivateLast Round
Series A
Oct 6, 2026
Total Funding Raised
$16.21M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Archeon Medical operates in Healthcare & Life Sciences and is based in Besançon. Its latest recorded funding round was a Series A round in October 2026.
Archeon Medical is a medical technology company that develops AI-powered ventilation feedback devices to improve manual ventilation and CPR outcomes for emergency medical services.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical AI, Sensors
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Archeon Medical Comparables
Compare Archeon Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SafeBVM Corporation | 81% | |
| Asahi Kasei | 78% | |
| Compact Medical | 77% |
For institutional investors. Book with your work email.
Archeon Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 6, 2026 | ||||
| Early Funding | Jun 27, 2024 | ||||
| Series A | Mar 16, 2022 | ||||
| Grant | Sep 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Archeon Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Karot Capital | Series A |
| UI Investissement | Series A |
| European Regional Development Fund | Series A |
| Daphni | Series A |
| Bpifrance | Series A, Early Funding |
| BNP Paribas | Early Funding |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
$9M round led by Newfund Capital.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 7, 2026
archeon-medical.com closes a $9M Series A equity round led by Newfund’s HEKA fund, with participation from Eiffel Investment Group, UI Investissement, Majycc Innovation Santé, and Karot Capital, to advance US clinical validation and commercial scale-up of EOlife on Oct 6th '26.
For institutional investors. Book with your work email.
Archeon Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Archeon Medical's valuation, stock price, and market status.
Is Archeon Medical a public or private company?
Archeon Medical is a private company.
What is the current stock price of Archeon Medical?
Archeon Medical is a private company, so its shares have no public market price. Caplight tracks Archeon Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Archeon Medical worth (valuation)?
Valuation information for Archeon Medical is not publicly available.
Can I buy Archeon Medical stock?
Archeon Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Archeon Medical's last funding round?
Archeon Medical's most recent funding round was Series A on October 6, 2026.
Who are the main investors in Archeon Medical?
Key investors in Archeon Medical include Karot Capital, Daphni, Bpifrance, Newfund Capital.
Will Archeon Medical IPO soon?
No public IPO plans have been announced for Archeon Medical.
How can I track Archeon Medical secondary market activity?
Caplight tracks bids, offers, and trades in Archeon Medical's shares on secondary markets.